Tags

Type your tag names separated by a space and hit enter

Vaccine against norovirus.
Hum Vaccin Immunother. 2014; 10(6):1449-56.HV

Abstract

Noroviruses (NoVs) are important pathogens causing epidemic acute gastroenteritis affecting millions of people worldwide. Due to the inability to cultivate NoVs, current NoV vaccine development relies on bioengineering technologies to produce virus-like particles (VLPs) and other subviral particles of NoVs as subunit vaccines. The first VLP vaccine has reached phase II clinical trials and several others are under development in pre-clinical research. Several subviral complexes made from the protruding (P) domains of NoV capsid share common features of easy production, high stability and high immunogenicity and thus are candidates for low cost vaccines. These P domain complexes can also be used as vaccine platforms to present foreign antigens for potential dual vaccines against NoVs and other pathogens. Development of NoV vaccines also faces other challenges, including genetic diversity of NoVs, limit understanding of NoV immunology and evolution, and lack of an efficient NoV animal model for vaccine assessment, which are discussed in this article.

Links

Publisher Full Text
ncbi.nlm.nih.gov
tandfonline.com
PMC Free PDF

Authors+Show Affiliations

Tan M
Division of Infectious Diseases; Cincinnati Children's Hospital Medical Center; Cincinnati, OH USA; Department of Pediatrics; University of Cincinnati College of Medicine; Cincinnati, OH USA.
Jiang X
Division of Infectious Diseases; Cincinnati Children's Hospital Medical Center; Cincinnati, OH USA; Department of Pediatrics; University of Cincinnati College of Medicine; Cincinnati, OH USA.

MeSH

Caliciviridae InfectionsClinical Trials, Phase II as TopicDrug DiscoveryGastroenteritisGenetic VariationHumansNorovirusVaccines, SyntheticViral Vaccines

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Review

Language

eng

PubMed ID

24718366

Citation

Tan, Ming, and Xi Jiang. "Vaccine Against Norovirus." Human Vaccines & Immunotherapeutics, vol. 10, no. 6, 2014, pp. 1449-56.
Tan M, Jiang X. Vaccine against norovirus. Hum Vaccin Immunother. 2014;10(6):1449-56.
Tan, M., & Jiang, X. (2014). Vaccine against norovirus. Human Vaccines & Immunotherapeutics, 10(6), 1449-56. https://doi.org/10.4161/hv.28626
Tan M, Jiang X. Vaccine Against Norovirus. Hum Vaccin Immunother. 2014;10(6):1449-56. PubMed PMID: 24718366.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vaccine against norovirus. AU - Tan,Ming, AU - Jiang,Xi, Y1 - 2014/05/05/ PY - 2014/4/11/entrez PY - 2014/4/11/pubmed PY - 2015/6/3/medline KW - P particle KW - VLP vaccine KW - calicivirus KW - norovirus KW - vaccine platform SP - 1449 EP - 56 JF - Human vaccines & immunotherapeutics JO - Hum Vaccin Immunother VL - 10 IS - 6 N2 - Noroviruses (NoVs) are important pathogens causing epidemic acute gastroenteritis affecting millions of people worldwide. Due to the inability to cultivate NoVs, current NoV vaccine development relies on bioengineering technologies to produce virus-like particles (VLPs) and other subviral particles of NoVs as subunit vaccines. The first VLP vaccine has reached phase II clinical trials and several others are under development in pre-clinical research. Several subviral complexes made from the protruding (P) domains of NoV capsid share common features of easy production, high stability and high immunogenicity and thus are candidates for low cost vaccines. These P domain complexes can also be used as vaccine platforms to present foreign antigens for potential dual vaccines against NoVs and other pathogens. Development of NoV vaccines also faces other challenges, including genetic diversity of NoVs, limit understanding of NoV immunology and evolution, and lack of an efficient NoV animal model for vaccine assessment, which are discussed in this article. SN - 2164-554X UR - https://www.unboundmedicine.com/medline/citation/24718366/Vaccine_against_norovirus_ L2 - https://www.tandfonline.com/doi/full/10.4161/hv.28626 DB - PRIME DP - Unbound Medicine ER -